Gemini Therapeutics (GMTX) Stock Price, News & Analysis

Company Overview

Gemini Therapeutics (NASDAQ:GMTX) is a clinical‐stage biotechnology company focused on the discovery and development of integrin‐targeting therapies for fibrotic diseases. Leveraging a proprietary antibody discovery platform, Gemini identifies and optimizes highly selective inhibitors of integrin subunits that play a key role in activating transforming growth factor‐β (TGF-β), a central driver of tissue fibrosis. The company’s approach is designed to block fibrotic signaling at its source, potentially offering improved safety and efficacy profiles compared with broader anti‐fibrotic agents.

Gemini’s lead programs are directed toward chronic kidney disease and idiopathic pulmonary fibrosis, two areas with significant unmet medical need and limited treatment options. In preclinical studies, Gemini’s integrin‐targeting antibodies have shown the ability to reduce tissue scarring and preserve organ function. The company is advancing its most advanced candidates toward investigational new drug (IND) applications, while also exploring additional indications in ocular and hepatic fibrosis where integrin biology may offer therapeutic benefit.

Headquartered in Cambridge, Massachusetts, Gemini Therapeutics was founded by a team of scientists and industry veterans with deep expertise in antibody engineering, fibrosis biology and clinical development. The company’s leadership includes professionals with prior experience at leading biopharmaceutical firms and academic institutions. Gemini collaborates with academic research centers and contract research organizations in North America and Europe to support preclinical and clinical programs, with the goal of bringing novel anti‐fibrotic therapies to patients worldwide.

Key Stats

• Today's Range: $68.82 to $70.89
• 50-Day Range: $57.07 to $70.75
• 52-Week Range: $1.16 to $14.10
• Volume: 310,503 shs
• Average Volume: 189,291 shs
• Market Capitalization: $3.03 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GMTX Stock Analysis - Frequently Asked Questions

How have GMTX shares performed this year?

Gemini Therapeutics' stock was trading at $63.40 at the beginning of 2025. Since then, GMTX shares have increased by 10.3% and is now trading at $69.90.

How were Gemini Therapeutics' earnings last quarter?

Gemini Therapeutics, Inc. (NASDAQ:GMTX) announced its earnings results on Monday, November, 15th. The company reported ($0.43) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.04.

How do I buy shares of Gemini Therapeutics?

Shares of GMTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Gemini Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Gemini Therapeutics investors own include Alphabet (GOOG), Meta Platforms (META), NVIDIA (NVDA), Zoom Communications (ZM), Activision Blizzard (ATVI), Fiverr International (FVRR) and

Company Calendar

• Last Earnings: 11/15/2021
• Today: 10/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GMTX
• CIK: 1816736
• Web: www.geminitherapeutics.com
• Phone: 415-877-4887
• Fax: N/A
• Employees: 30
• Year Founded: 2015

Profitability

• EPS (Trailing Twelve Months): ($1.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$71.87 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -38.78%
• Return on Assets: -35.88%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 71.49
• Quick Ratio: 71.49

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.89 per share
• Price / Book: 24.48

Miscellaneous

• Outstanding Shares: 43,328,000
• Free Float: 37,739,000
• Market Cap: $3.07 billion
• Optionable: Not Optionable
• Beta: -0.12